Targeted therapies based on the combined BRAF and MEK inhibition also exert a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, with no brain metastases, and low tumor burden while elevated LDH, high tumor burden and brain metastasis should be considered as negative predictive factors [18]. This evidence concerns the gene MAP2K7 and neoplasm.